Bridgeway Capital Management’s Akebia Therapeutics AKBA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$92K Buy
+100,000
New +$108K ﹤0.01% 1135
2017
Q2
– Sell
-65,000
Closed -$598K – 1411
2017
Q1
$598K Hold
65,000
– – 0.01% 1000
2016
Q4
$677K Hold
65,000
– – 0.01% 956
2016
Q3
$588K Hold
65,000
– – 0.01% 1019
2016
Q2
$486K Sell
65,000
-16,250
-20% -$142K 0.01% 1059
2016
Q1
$732K Sell
81,250
-15,400
-16% -$125K 0.01% 900
2015
Q4
$1.25M Hold
96,650
– – 0.02% 658
2015
Q3
$934K Hold
96,650
– – 0.02% 772
2015
Q2
$995K Buy
96,650
+65,000
+205% +$555K 0.02% 790
2015
Q1
$352K Buy
+31,650
New +$337K 0.01% 1210

Other funds holding AKBA

Bridgeway Capital Management's AKBA Position: Q3 2026 in Review

Bridgeway Capital Management opened a new position in Akebia Therapeutics (AKBA) in Q3 2026: 100,000 shares worth $92K. The stake represents ﹤0.01% of the portfolio and ranks #1135 among its holdings. This is a return to the name: Bridgeway Capital Management previously reported a position in AKBA as recently as Q1 2017.

Bridgeway Capital Management first reported a position in AKBA in Q1 2015 and has held it in 10 quarters since. The position peaked at $1.25M in Q4 2015. 156 funds tracked by Wall St. Rank hold AKBA as of Q3 2026.

  • Bridgeway Capital Management held 100,000 shares of Akebia Therapeutics worth $92K as of Q3 2026.
  • Akebia Therapeutics was a new Bridgeway Capital Management position in Q3 2026.
  • Akebia Therapeutics made up ﹤0.01% of Bridgeway Capital Management's portfolio in Q3 2026, its #1135 holding.
  • Bridgeway Capital Management first reported a position in Akebia Therapeutics in Q1 2015 and has held it in 10 quarters since.
  • Bridgeway Capital Management's Akebia Therapeutics position peaked at $1.25M in Q4 2015.
  • 156 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q3 2026.

Based on Bridgeway Capital Management's 13F filing for Q3 2026, filed 16 Nov 2026.